Clinical Trials, Phase I as Topic
-
Subject Areas on Research
-
A Rational Approach to Target the Epidermal Growth Factor Receptor in Glioblastoma.
-
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24.
-
A hybrid Bayesian adaptive design for dose response trials.
-
A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469.
-
A repeated measures model for analysis of continuous outcomes in sequential parallel comparison design studies.
-
A systematic review of randomized controlled trials for the prevention of bronchopulmonary dysplasia in infants.
-
ALSUntangled No. 35: Hyperbaric Oxygen Therapy.
-
Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.
-
Adaptive clinical trial design.
-
Adjuvanting a subunit COVID-19 vaccine to induce protective immunity.
-
An exploration of relative health stock in advanced cancer patients.
-
An intervention to improve cancer patients' understanding of early-phase clinical trials.
-
An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral.
-
Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation.
-
Antiretroviral therapy: evaluating the new era in HIV treatment.
-
Application of chemoproteomics to drug discovery: identification of a clinical candidate targeting hsp90.
-
Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer.
-
CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer.
-
Cabozantinib in genitourinary malignancies.
-
Clinical outcomes and factors predicting development of venous thromboembolic complications in patients with advanced refractory cancer in a Phase I Clinic: the M. D. Anderson Cancer Center experience.
-
Clinical studies of angiogenesis inhibitors: the University of Texas MD Anderson Center Trial of Human Endostatin.
-
Clinical uses of pegylated pharmaceuticals in oncology.
-
Combining classification trees using MLE
-
Comment regarding benefit in phase 1 oncology trials.
-
Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma.
-
Concurrent chemotherapy and intensity-modulated radiotherapy for organ preservation of locoregionally advanced oral cavity cancer.
-
Consent forms and the therapeutic misconception: the example of gene transfer research.
-
Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2.
-
Development and utilization of a combined LC-UV and LC-MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin.
-
Eptifibatide in percutaneous coronary intervention. A review.
-
Evaluation and recommendations on good clinical laboratory practice guidelines for phase I-III clinical trials.
-
Evaluation of ventricular arrhythmias in early clinical pharmacology trials and potential consequences for later development.
-
Everolimus in colorectal cancer.
-
Extending principles learned in model systems to clinical trials design.
-
Future directions in regional treatment strategies for melanoma and sarcoma.
-
GNOSIS: guidelines for neuro-oncology: standards for investigational studies-reporting of phase 1 and phase 2 clinical trials.
-
Genome-editing Technologies for Gene and Cell Therapy.
-
HIV type 1 vaccine-induced cytotoxic T cell responses in phase I clinical trials: detection, characterization, and quantitation.
-
HIV vaccines. Viral envelope fails to deliver?
-
Inhibition of poxvirus growth by Terameprocol, a methylated derivative of nordihydroguaiaretic acid.
-
Integrative gene expression profiling reveals G6PD-mediated resistance to RNA-directed nucleoside analogues in B-cell neoplasms.
-
Is there a palliative benefit of gemcitabine plus fluoropyrimidines in patients with refractory colorectal cancer? A review of the literature previously presented: poster at the 2008 Gastrointestinal Cancer Symposium (Abstract No. 512).
-
Longitudinal Impact of Acute Spinal Cord Injury on Clinical Pharmacokinetics of Riluzole, a Potential Neuroprotective Agent.
-
Mammalian target of rapamycin inhibition.
-
Modulation of the Coagulation Cascade Using Aptamers.
-
Monoclonal antibodies for brain tumour treatment.
-
New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis.
-
Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.
-
Patient expectations of benefit from phase I clinical trials: linguistic considerations in diagnosing a therapeutic misconception.
-
Perceptions of patients and physicians regarding phase I cancer clinical trials: implications for physician-patient communication.
-
Phase 1 clinical trials of the National Institutes of Health Vaccine Research Center HIV/AIDS candidate vaccines.
-
Phase I participants' views of quality of life and trial participation burdens.
-
Phase I studies with the novel nucleoside analog gemcitabine.
-
Phase I trial design: are new methodologies being put into practice?
-
Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304).
-
Plasma Metabolites and Risk of Radiation-induced Esophagitis: A Secondary Analysis from a Prospective Study.
-
Population pharmacokinetics of vactosertib, a new TGF-β receptor type Ι inhibitor, in patients with advanced solid tumors.
-
Prasugrel, a third generation thienopyridine and potent platelet inhibitor.
-
Prasugrel.
-
Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody.
-
Predictors of Delayed Cerebral Ischemia in Patients with Aneurysmal Subarachnoid Hemorrhage with Asymptomatic Angiographic Vasospasm on Admission.
-
Prevalence and impact of correlative science in breast cancer phase II trials.
-
Production and quality control assessment of a GLP-grade immunotoxin, D2C7-(scdsFv)-PE38KDEL, for a phase I/II clinical trial.
-
Prostate cancer gene therapy.
-
Quality of potent Mn porphyrin-based SOD mimics and peroxynitrite scavengers for pre-clinical mechanistic/therapeutic purposes.
-
RNA as performance-enhancers for dendritic cells.
-
Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia.
-
Rationale of technical requirements for NRG-BR001: The first NCI-sponsored trial of SBRT for the treatment of multiple metastases.
-
Recommendations for clinical trial evaluation of acute stroke therapies.
-
Research participants' high expectations of benefit in early-phase oncology trials: are we asking the right question?
-
Role of etoposide (VP-16) in preparatory regimens for patients with leukemia or lymphoma undergoing allogeneic bone marrow transplantation.
-
Strategies to enhance the efficacy of intravescical therapy for non-muscle invasive bladder cancer.
-
Study of the media's potential influence on prospective research participants' understanding of and motivations for participation in a high-profile phase I trial.
-
Successful Translation of Fluorescence Navigation During Oncologic Surgery: A Consensus Report.
-
Technology evaluation: Rexin-G, Epeius Biotechnologies.
-
The clinical and financial impact of a pediatric surgical neuro-oncology clinical trial.
-
The correlation between patient characteristics and expectations of benefit from Phase I clinical trials.
-
The role of amifostine as a radioprotector.
-
Therapeutic misconception in early phase gene transfer trials.
-
Uncertain benefit: investigators' views and communications in early phase gene transfer trials.
-
Understanding of an aggregate probability statement by patients who are offered participation in Phase I clinical trials.
-
Update of the international consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases.
-
Use of murine models of cytokine-secreting tumor vaccines to study feasibility and toxicity issues critical to designing clinical trials.
-
Using immunotherapy to target EGF in patients with NSCLC.
-
Varieties of uncertainty and the validity of informed consent.
-
Vinorelbine (Navelbine) in non-small cell lung cancer: future directions.
-
Keywords of People
-
Berchuck, Andrew,
James M. Ingram Distinguished Professor of Gynecologic Oncology,
Obstetrics and Gynecology, Gynecologic Oncology
-
Pang, Herbert,
Adjunct Assistant Professor in the Department of Biostatistics & Bioinformatics,
Biostatistics & Bioinformatics
-
Thomas, Melanie Byrne,
Associate Professor of Medicine,
Medicine, Medical Oncology
-
West, Vivian L,
Clinical Associate in the School of Nursing,
School of Nursing